Antisense News and Research

RSS

Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.

Findings could lead to new therapy for spinal cord injury

Research led by scientists at the University of California, San Diego (UCSD) School of Medicine has identified a target with potential as an effective new therapy for chronic spasticity and rigidity, a painful condition that often results from spinal cord injury.

17 Oct 2007

Researchers specifically manipulate tumor angiogenesis gene

Angiogenesis is a common process that is essential for tumor growth beyond 2 mm. Although numerous growth factors are involved, vascular endothelial growth factor (VEGF), particularly VEGF-A, has been shown to play an important role in tumor angiogenesis.

16 Oct 2007

Isis Pharmaceuticals awarded $1.5 million NIH grant to improve RNAi-based therapeutics

Isis Pharmaceuticals, Inc. has announced that it has been awarded a multi-year Phase 2 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH) for up to $1.5 million to design oligonucleotide drugs that can exploit the RNA interference (RNAi) antisense mechanism for disease treatment.

4 Oct 2007

microRNAs may be key to HIV's ability to hide, evade drugs

Tiny pieces of genetic material called microRNA (miRNA), better known for its roles in cancer, could be a key to unlocking the secrets of how HIV, the AIDS virus, evades detection, hiding in the immune system.

1 Oct 2007

eIF4E-specific anti-sense oligonucleotides knock down cancer

A new study by Jeremy Graff and colleagues from Eli Lilly and Company has demonstrated the anti-cancer effect of a new therapeutic in a mouse model of human tumors and has spawned clinical trials to test the ability of this therapeutic to treat human cancers.

5 Sep 2007

Bristol-Myers Squibb collaborates with Isis Pharmaceuticals

Bristol-Myers Squibb Company and Isis Pharmaceuticals have announced a collaboration to discover, develop and commercialize novel antisense drugs targeting proprotein convertase subtilisin kexin 9 (PCSK9) for the prevention and treatment of cardiovascular disease.

10 May 2007

Almac announces study on colorectal pre-malignancies

Almac Diagnostics has announced a major study analysing colorectal polyp tissue samples using its novel Colorectal Cancer DSA microarray.

5 Apr 2007

Nanoparticles yield delivery tools for therapeutic nucleic acids

Cancer researchers hold great hope that nucleic acid-based therapeutics, such as anticancer genes, antisense oligonucleotides, and small interfering RNA (siRNA) molecules, will prove to be powerful antitumor agents.

16 Jan 2007

Nanotechnology continues to advance anticancer gene therapy

Given that cancer is a disease in which genetic errors play a major role, it should come as no surprise that many experts envision a time when gene therapy will play an equally important role in the treatment of cancer.

20 Nov 2006

Scientists discover function for antisense RNA

Researchers have found that a class of RNA molecules, previously thought to have no function, may in fact protect sex cells from self-destructing. These findings will be published in the November 17 issue of the journal Cell.

20 Nov 2006

Inhibiting a particular cancer-causing gene improves radiation effectiveness

Inhibiting a particular cancer-causing gene can enhance the cell-killing effects of radiation, a team of radiation oncologists and cancer biologists at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia has found.

8 Nov 2006

Phase I clinical trial of experimental gene therapy to treat HIV shows encouraging results

The results of a Phase I clinical trial of an experimental gene therapy aimed at treating HIV indicate that the therapy is safe and effective and also might sustain viral loads, according to a study published on Monday in the online edition of the Proceedings of the National Academy of Sciences, the AP/Washington Post reports.

8 Nov 2006

Promising therapy for Lou Gehrig's disease delivers antisense drug directly to nervous system

Researchers have designed and tested a molecular therapy in animals that they hope will be a major development in the fight to treat amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease.

27 Jul 2006

Potential novel treatment strategy for Ewing's sarcoma

Using molecular and cell-based models, researchers at Georgetown University Medical Center have refined the picture of how a cancer-promoting protein associated with Ewing's sarcoma functions.

1 Jun 2006

Weill Cornell experts publish review of genetic medicine

In an article published in the April issue of Nature Reviews Genetics, two experts at the Weill Medical College of Cornell University sum up the achievements, challenges and promise of a burgeoning field: genetic medicine.

3 Apr 2006

Ocean Vesivirus found in human blood samples

A virus of ocean origin that can cause a range of diseases in several animal species has been found in human blood samples. The virus, or antibodies to it, was found most often in the blood of individuals with liver damage, or hepatitis of unknown cause related to blood exposure.

28 Mar 2006

Bioniche granted patent for oligonucleotide technology

Bioniche Life Sciences has announced that it has been granted a European patent - EP1432450 - covering the composition and use of a novel oligonucleotide family for the treatment of cancer entitled: "Therapeutically Useful Triethyleneglycol Cholesteryl Oligonucleotides"

17 Mar 2006

Antisense molecules may hold promise in treating brain chemical problems such as Alzheimer's

Saint Louis University research shows a new class of drugs may hold promise in treating brain chemical problems such as Alzheimer's disease, says the principal investigator of research published in an early on-line version of Peptides.

25 Oct 2005

Pursuit of potential drugs and small molecules that target the IGF-1 receptor

Pharmaceutical companies around the world still come knocking on Renato Baserga, M.D.,'s door. And for good reason.

27 Sep 2005

Significant new breakthroughs in understanding how the genes in mammals are controlled

An international consortium of genome research institutes and investigators, including Jackson Laboratory Staff Scientists Carol J. Bult, Ph.D., and Martin Ringwald, Ph.D., has reported significant new breakthroughs in understanding how the genes in mammals are controlled.

6 Sep 2005